ABOVE: © ISTOCK.COM, TOMSMITH585
Update (August 25): The National Institutes of Health has said it will be conducting preclinical research on GS-441524 as a potential COVID-19 treatment. In a letter dated August 20, the director of the agency’s National Center for Advancing Translational Sciences wrote: “We are planning to independently test the therapeutic hypothesis for GS-441524 in treating SARS-CoV-2. . . . We expect to conduct these studies quickly and make the results available to the research community for further consideration.”
Gilead Sciences, the maker of remdesivir, is under pressure from citizen advocates to launch clinical trials on COVID-19 patients of another of its compounds—one that advocates claim could be cheaper, easier to make, and more effective at treating the novel coronavirus.
Remdesivir is currently the only medication to have emergency use authorization from the US Food and Drug Administration (FDA) for hospitalized COVID-19 patients. In a letter posted last ...
